Wednesday, July 8, 2026

pharma · Peripheral Artery Disease · Muscle-Invasive Bladder Carcinoma

Blackmores Institute

Blackmores Institute is a pharma organization headquartered in Warriewood, AU. Primary therapeutic focus areas include Peripheral Artery Disease, Muscle-Invasive Bladder Carcinoma, Therapeutic Equivalency, Solid Tumor, A

20 Jubilee Ave, Warriewood, New South Wales 2102, AU HQ
2012 Founded
27 Employees
TGA registrant Type
Company details
Status
Public
HQ
20 Jubilee Ave, Warriewood, New South Wales 2102, AU
Founded
2012
Employees
27
Programs
17
Drugs
24
Patents
38
Clinical program

YF476

Phase 1 · small molecule · Hypergastrinaemia

YF476 for Hypergastrinaemia is a Phase 1 program (small_molecule) at Blackmores Limited with 2 ClinicalTrials.gov record(s).

← All Blackmores Limited projects Phase 1 small molecule completed

Internal code 01-023

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Blackmores Limited
Phase
Phase 1
Modality
small_molecule
Indication
Hypergastrinaemia
Status
completed
Trials
2

Clinical trials